Background: SU2162, a novel anticancer agent, was investigated in the rat, and pharmacokinetics and tissue distribution were observed. These data will be used to design a SU2162 dosage form for clinical use.
Methods: After IV administration of SU2162, HPLC with UV detection was used to analyze rat samples. A two compartment model was used to evaluate the pharmacokinetics of SU2162.
Results: SU2162 pharmacokinetics in the rat depicts a two-compartment model, and the weighting coefficient was 1/c2. The distribution half life (T1/2α) was 0.1066 h; the elimination half life (T1/2kel) was 0.3910 h. SU2162 was distributed widely in tissues studied. The AUC in the spleen was the highest of all the tissues assayed (6.7685 mg/l*h). The LZ in the liver was the greatest (1.5729 1/h) but liver MRT was the smallest (0.6760 h).
Conclusion: SU2162 is eliminated quickly in the rat and distributes to tissues extensively, and warrants further development as anticancer candidate.
Keywords: SU2162, pharmacokinetics, tissue distribution, compartment model, HPLC